Arsenic trioxide (ATO) up-regulates cytochrome P450 1A (CYP1A) enzymes in murine hepatoma Hepa-1c1c7 cell line.

[1]  A. El-Kadi,et al.  Mercury and methylmercury differentially modulate hepatic cytochrome P450 1A1 and 1A2 in vivo and in vitro , 2022, Journal of biochemical and molecular toxicology.

[2]  A. El-Kadi,et al.  The Duality of Arsenic Metabolism: Impact on Human Health. , 2022, Annual review of pharmacology and toxicology.

[3]  A. El-Kadi,et al.  Down-regulation of hepatic cytochromes P450 1A1 and 1A2 by arsenic trioxide (ATO) in vivo and in vitro: A role of heme oxygenase 1. , 2022, Chemico-biological interactions.

[4]  S. Jehan,et al.  Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy , 2022, Pharmaceutics.

[5]  K. Kerl,et al.  Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors , 2021, Medicinal research reviews.

[6]  A. El-Kadi,et al.  Arsenic: Various species with different effects on cytochrome P450 regulation in humans , 2021, EXCLI journal.

[7]  Hua Naranmandura,et al.  Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. , 2020, Metallomics : integrated biometal science.

[8]  Jian Lu,et al.  New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases , 2019, Acta pharmaceutica Sinica. B.

[9]  Y. Duan,et al.  Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment , 2019, Signal Transduction and Targeted Therapy.

[10]  Vaibhav Jadhav,et al.  Arsenic trioxide: insights into its evolution to an anticancer agent , 2018, JBIC Journal of Biological Inorganic Chemistry.

[11]  C. Wolf,et al.  Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[12]  A. El-Kadi,et al.  Down-regulation of cytochrome P450 1A1 by monomethylarsonous acid in human HepG2 cells. , 2017, Toxicology letters.

[13]  L. Klotz,et al.  Methylated pentavalent arsenic metabolites are bifunctional inducers, as they induce cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase through AhR- and Nrf2-dependent mechanisms. , 2014, Free radical biology & medicine.

[14]  Anwar Anwar-mohamed,et al.  Differential modulation of cytochrome P450 1a1 by arsenite in vivo and in vitro in C57BL/6 mice. , 2013, Free radical biology & medicine.

[15]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology and Therapeutics.

[16]  M. Siddiqui,et al.  Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells , 2013, OncoTargets and therapy.

[17]  J. Zhao,et al.  Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  Bo Wang,et al.  Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 , 2010, Drug metabolism reviews.

[19]  Paavo Honkakoski,et al.  Inhibition and induction of human cytochrome P450 enzymes: current status , 2008, Archives of Toxicology.

[20]  A. El-Kadi,et al.  The role of redox-sensitive transcription factors NF-kappaB and AP-1 in the modulation of the Cyp1a1 gene by mercury, lead, and copper. , 2008, Free radical biology & medicine.

[21]  A. El-Kadi,et al.  Transcriptional activation and posttranscriptional modification of Cyp1a1 by arsenite, cadmium, and chromium. , 2007, Toxicology letters.

[22]  A. El-Kadi,et al.  The role of oxidative stress in the modulation of aryl hydrocarbon receptor-regulated genes by As3+, Cd2+, and Cr6+. , 2005, Free radical biology & medicine.

[23]  A. El-Kadi,et al.  Regulatory mechanisms modulating the expression of cytochrome P450 1A1 gene by heavy metals. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  N. Ariyoshi,et al.  CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. , 2005, Current drug metabolism.

[25]  Ying Xia,et al.  Arsenite-Induced Aryl Hydrocarbon Receptor Nuclear Translocation Results in Additive Induction of Phase I Genes and Synergistic Induction of Phase II Genes , 2005, Molecular Pharmacology.

[26]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[27]  L. Kaminsky,et al.  Polycyclic aromatic hydrocarbon/metal mixtures: effect on PAH induction of CYP1A1 in human HEPG2 cells. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[28]  A. Murgo.  Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. , 2001, The oncologist.

[29]  S. Waxman,et al.  History of the development of arsenic derivatives in cancer therapy. , 2001, The oncologist.

[30]  J. Bend,et al.  Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells. , 1997, Molecular pharmacology.

[31]  S. Kennedy,et al.  A fluorescence-based protein assay for use with a microplate reader. , 1993, Analytical biochemistry.

[32]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.